Overview of Nicergoline Amel

Property	Description
Active ingredient	Nicergoline
Form	Tablet (Oral) / Lyophilisate (Parenteral)
Pharmacological class	Alpha-1 adrenergic receptor antagonist
Common use	Supporting cerebral and vascular health
Origin	Semisynthetic ergot derivative

Nicergoline Amel is a prescription medication whose active substance, Nicergoline, is used to support cerebral blood flow and enhance the metabolic functions of the brain. The drug is classified by the WHO Anatomical Therapeutic Chemical (ATC) system under the category C04A, designated for peripheral vasodilators. This classification is clinically recognized for its use in circulatory support. Nicergoline is fundamentally classified as an alpha-1 adrenergic receptor antagonist, which places it within the therapeutic groups of Vasodilators and Nootropic Agents.

What Type of Medicine is Nicergoline Amel?

Nicergoline Amel is primarily an alpha-1 adrenergic receptor antagonist, a type of drug that works by selectively blocking specific receptors on the walls of blood vessels. This action results in vasodilation, meaning it helps to widen the blood vessels, particularly those supplying the brain. Nicergoline acts as a therapeutic agent by enhancing cerebral metabolism and improving blood flow in the brain. This indicates that the medication is designed to make the brain’s internal environment more efficient.

Its pharmacological action is designed to support the vascular system in the central nervous system, helping to optimize the delivery of oxygen and glucose. Its general purpose is to aid in the maintenance of cognitive performance and overall vascular health when these functions are compromised. Nicergoline also exhibits properties of inhibiting platelet aggregation, contributing to its overall vascular support profile.

Nicergoline: Semisynthetic Origin and Composition

The medicine is a single-ingredient product featuring Nicergoline, a compound classified as a semisynthetic ergot derivative. This means the active substance is chemically modified from the basic structure of naturally occurring ergot alkaloids to enhance its specific therapeutic effects and selectivity. Nicergoline Amel is typically available as a prescription-only (Rx) product, positioning it for use under professional supervision. It is manufactured in forms suitable for both oral use, typically as tablets, and parenteral use, such as a preparation for injection, defining its versatility in clinical application.

What side effects are possible with Nicergoline Amel?

Possible side effects and safety information

The official safety profile of Nicergoline Amel is categorized by regulatory bodies to communicate potential adverse reactions and constraints related to its use as an alpha-1 adrenergic receptor antagonist and semisynthetic ergot derivative. All documented effects and restrictions are based strictly on government regulatory sources.

Adverse Reaction Scope

Commonly documented adverse reactions primarily involve the Gastrointestinal System (e.g., nausea, dry mouth, diarrhea, constipation), the Nervous System (e.g., dizziness, headache, sleepiness), and the Vascular System (e.g., hypotension and hot flush). These effects are frequently classified as common in regulatory summaries, reflecting the drug's primary action.

Less common reactions documented in the regulatory classification framework include bradycardia and various skin reactions.

Serious Adverse Reactions and Class Risks

As an ergot derivative, Nicergoline is officially associated with a class risk of rare but serious reactions, specifically various forms of fibrosis (e.g., retroperitoneal, pulmonary, or cardiac valve fibrosis) and the potential for ergotism. Regulatory agencies explicitly note that the risk of fibrotic reactions is associated with long-term exposure to the medication.

Safety Constraints and Special Populations

Official prescribing information defines explicit conditions under which Nicergoline Amel is contraindicated, including recent myocardial infarction, severe hypotension, severe bradycardia, and acute bleeding.

Caution is also required, and dose adjustment may be necessary for patients with renal impairment. Use in the pediatric population and during pregnancy or lactation is generally not recommended as safety and efficacy have not been formally established in these groups.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Nicergoline Amel focuses on acute circulatory effects and regulator-mandated emergency actions. When a dose larger than prescribed is taken, the instruction is to immediately contact specialists to provide timely medical care.

Documented Overdose Manifestations and Actions

Classification	Official Regulatory Statement
Primary Manifestation	A transient pronounced decrease in blood pressure (hypotension) is the main documented clinical sign.
Urgent Action	Immediate medical help is required for exceptional cases involving a sharp violation of the blood supply to the brain and heart.
Supportive Measures	Management is generally symptomatic. Initial steps for hypotension involve placing the patient in a horizontal position for a few minutes.
Pharmacological Intervention	In severe, exceptional cases, the introduction of sympathomimetic medicines is recommended under constant blood pressure control.

Official Constraints and Risk

No specific antidote is known for Nicergoline overdose; therefore, management relies entirely on supportive care and observation. Furthermore, specific attention is given to patients with impaired renal function in the regulatory documents, as the excretion of drug metabolites is reduced, posing an increased risk of overexposure that must be considered in the context of dosing and safety.

Therapeutic Uses of Nicergoline Amel

What Nicergoline Amel Treats: Main Uses and Benefits

Nicergoline Amel is commonly used to help with symptoms related to systemic imbalance in conditions characterized by periods of heightened symptoms. This includes addressing symptoms that interfere with daily functioning, such as age-related memory loss and reduced mental clarity, and is considered relevant during the rehabilitation phase following chronic ischaemic stroke. The medication is used across domains where additional symptomatic support is needed.

It assists with managing symptom clusters that may become intense or disruptive, such as chronic dizziness, feelings of unsteadiness, and bothersome tinnitus (noises in the ears). Nicergoline Amel is applied in situations where these symptoms interfere with daily functioning, and contributes to improved comfort during periods of heightened symptoms.

Furthermore, it is relevant for conditions presenting with systemic or localized discomfort in the limbs and certain conditions linked to organ-specific functional stress in the eye, such as diabetic retinopathy. For these uses, it provides supportive relief when symptoms interfere with daily functioning.

“The application contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Support for Vascular-Related Dizziness

Eligibility and Restrictions for Use

Nicergoline Amel's official eligibility profile is strictly defined by regulatory documents, allowing its use primarily in the adult population, particularly the elderly. Use is formally not recommended for children and adolescents under 18 years, as the safety and efficacy of the medicine are not established in these age groups. Administration during pregnancy or lactation is also not recommended; if treatment is considered essential, breastfeeding must be suspended.

The following populations are either prohibited from using the medicine or require special caution:

Absolute Contraindications (Must Not Use)	Conditional Use (Requires Caution)
Hypersensitivity to nicergoline or ergot derivatives.	Impaired renal function (kidney disease).
Recent myocardial infarction (heart attack).	Impaired hepatic function (liver disease).
Conditions with acute bleeding (e.g., after cerebral hemorrhage).	History of Porphyria, hyperuricemia, or gout.
Severe bradycardia or acute hypotension (collapse risk).	Conditions prone to orthostatic hypotension.

These population eligibility statements are defined by governmental regulatory documents, such as the Summary of Product Characteristics, to outline all patient exclusions or requirements for conditional use. The profile ensures that eligibility is determined solely by the patient's existing physiological state and medical history.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Nicergoline, based on regulatory labeling.

Pharmacodynamic and Class Restrictions

Co-administration with other ergot derivatives is a contraindicated combination due to the potential for serious reactions, including ergot toxicity characterized by peripheral vasospasm.

Combining Nicergoline with antihypertensive agents may result in an additive hypotensive effect, increasing the risk of an excessive blood pressure drop. Due to Nicergoline’s intrinsic antiplatelet activity, its use with anticoagulants or antiplatelet agents (such as Warfarin or Aspirin) increases the risk of bleeding, as officially documented. Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may be associated with an increased risk of hypertension.

Metabolic and Exposure Effects

Nicergoline is primarily metabolized by the CYP2D6 enzyme system. Concomitant use with strong CYP2D6 inhibitors (e.g., Fluoxetine, Paroxetine) is documented to decrease Nicergoline metabolism, leading to increased plasma exposure and a higher potential for effects.

Interaction severity is a relevant consideration for patients with impaired hepatic or renal function due to the dependence of the drug's clearance on these organs.

Mechanism of Action

Nicergoline exerts its physiological effects through multiple, complementary mechanisms that target core regulatory systems. The primary mechanism is Vascular Smooth Muscle Modulation, where the drug acts as a selective antagonist of alpha1-adrenergic receptors. Blocking these receptors interrupts the norepinephrine-mediated vasoconstrictive signals, resulting in the relaxation of vascular smooth muscle, a reduction in vascular resistance, and consequent increased arterial blood flow, particularly in the cerebral circulation.

Concurrently, the drug provides Neuronal and Metabolic Signaling Support. It modulates central nervous system function by facilitating the enzyme Choline Acetyltransferase (ChAT), which enhances Acetylcholine synthesis to modulate mechanisms associated with information processing. This action, along with the engagement of neurotrophic signaling pathways, leads to the increased utilization of oxygen and glucose by brain tissue. Finally, through Modulation of Microcirculatory Quality, Nicergoline inhibits platelet aggregation by disrupting intracellular signaling, which enhances the fluidity of the blood and ensures effective microcirculatory perfusion.

Dosage and Administration Information

The administration of Nicergoline Amel follows parameters detailing the specific route, dose, and duration of use, based on established product characteristics.

Administration Scope

Parameter	Instruction
Route of administration	The medicine is administered via oral use as tablets, or parenteral administration via intramuscular (IM), intravenous (IV) slow infusion, or intra-arterial injection.
Dosing schedule	The standard adult oral dose is 15 mg daily in three divided doses, such as 5 mg three times per day. The maximum oral daily dose is 60 mg.
Timing in relation to meals (if applicable)	Oral tablets are generally taken before meals.
Preparation requirements (if applicable)	For IV infusion, the injectable solution (4 mg to 8 mg) requires dilution in 100 mL of 0.9% NaCl or a 5–10% dextrose solution prior to slow administration.
Age-group administration rules	The medicine is not recommended for use in pediatric patients (under 18 years of age) due to a lack of established safety data.
Missed-dose rules	If an oral dose is missed, it is skipped if close to the next scheduled dose; the dose should not be doubled.
Special procedural conditions	Dosage may require adjustment for adult patients with known renal impairment.

Instruction Classifications (High-Level)

Parameter	Classification
Administration method type	Oral and Parenteral (IM, IV, Intra-arterial)
Frequency pattern	Daily (in divided doses)
Use-context constraints	Administration is discontinued if there is no clinical response at Week 12 of treatment.

Resulting Procedural Structure

Standard Step Sequence:

The oral form is taken three times per day, typically before meals, at a daily dose not exceeding the 60 mg maximum.
The parenteral forms are administered by a healthcare professional, with specific dilution requirements necessary for intravenous use.
The initial period of use is reviewed, with the medicine discontinued if no clinical response is observed after 12 weeks.

Connection to the Overall Use Protocol

Standard protocols establish that Nicergoline Amel is used as a standardized course of treatment, requiring a divided daily dose for the oral form and specific dilution for the injectable form. These parameters set clear guidelines for administration frequency, route selection, and the time-limited review point at Week 12 to maintain a consistent protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nicergoline Amel

Evidence for Cognitive and Behavioral Symptoms

The research base for Nicergoline's use in conditions associated with cognitive and behavioral impairment is largely formed by Randomized Controlled Trials (RCTs) focusing on older adults. Studies monitored changes using standardized psychometric tests for memory and attention, as well as clinical global impression scales. Studies observed patterns in measured assessment scores, including those related to behavioral symptoms. However, long-term effects are not fully established. Evidence quality varies across studies, and sample sizes were modest in studies evaluating severe cognitive decline. Research does not determine whether an individual will respond similarly.

Evidence for Vascular, Balance, and Peripheral Conditions

Nicergoline was studied for its use in conditions related to chronic insufficient blood flow to the brain, and research examined symptoms such as dizziness and unsteadiness. Studies report how symptoms evolved in the observed populations, sometimes documenting changes in subjective symptom severity and blood flow. The compound was also examined in peripheral vascular disorders, including those affecting the limbs and the eye. For these non-cognitive indications, the evidence is limited and often derived from older, smaller clinical studies, meaning certainty remains low regarding specific symptomatic relief.

Key Uncertainties and Research Gaps

Research provides context but not individual predictions, and the evidence highlights what is known — and what is still uncertain. Key research limitation frames include that the evidence quality varies across studies, and comparative evidence against newer treatments is often lacking. Nicergoline has not been evaluated using current diagnostic categories, such as Mild Cognitive Impairment (MCI). Long-term effects are not fully established, and regulatory sources have noted that the evidence base for certain historical uses is not strong enough to definitively characterize findings in modern clinical standards.

Key Studies & References

WHO ATC Classification: C04AE02 (Nicergoline)

Frequently Asked Questions (FAQ)

Common questions about Nicergoline Amel (FAQ)

Q: Can Nicergoline Amel affect sleep patterns?

Regulatory documents list side effects related to the central nervous system. These include reports of both sleepiness (somnolence) and, in some cases, insomnia as documented adverse reactions. If an individual experiences changes in their sleep patterns after starting the medicine, this may be a documented effect of the drug.

Q: Do I need to take Nicergoline Amel with food?

Official product information on the administration of the oral tablets often states that they are instructed to be taken before meals. This recommendation establishes the standardized condition of use for the oral formulation of the medication, as specified in regulatory documents.

Q: Is the research evidence for Nicergoline Amel considered strong or still developing?

Official regulatory summaries and reviews indicate that the evidence supporting therapeutic benefit varies in quality across studies. While evidence is supported for certain approved conditions, the evidence for some historical uses is limited. Furthermore, official sources note that the long-term effects of the medicine are not fully established in all contexts.

Q: Are there restrictions on driving or operating machinery while using Nicergoline Amel?

Regulatory warnings advise caution regarding driving or operating heavy machinery. Since Nicergoline can cause side effects like dizziness and sleepiness, patients are generally advised to refrain from performing these activities if they experience effects that interfere with their ability to operate safely.

Q: What are the differences between Nicergoline Amel and other Nicergoline formulations?

The medication is produced in different forms for use in various clinical settings. Official documents describe Nicergoline as available in both oral tablets and parenteral forms, such as a preparation for injection. The specific form used depends on the medical context and the intended administration method.

Q: How long does Nicergoline Amel stay in the body after the last dose?

The body’s clearance of Nicergoline is primarily handled by the metabolic processes in the liver and its excretion via the kidneys. The rate at which Nicergoline is cleared from the body is a process dependent on the function of these organs, as described in regulatory pharmacokinetic documents.

Q: Is Nicergoline Amel known by any other brand names globally?

Yes. The active pharmaceutical ingredient, Nicergoline, is sold under various trade names worldwide. International regulatory databases list common brand names, such as Sermion.

Q: How quickly should someone expect to feel any effects from Nicergoline Amel?

Evidence from clinical studies suggests that the effects of Nicergoline may take time to become measurable. Studies have indicated that measurable patterns of response in some symptoms may become apparent after approximately 2 months of consistent treatment, with some neurophysiological changes noted after four to eight weeks.

Q: Is it common to feel dizzy when starting Nicergoline Amel?

Yes. According to the official regulatory safety profile, dizziness is listed as a common adverse reaction to Nicergoline. This makes it one of the more frequent side effects documented during clinical assessment.

Q: Does Nicergoline Amel have any known food or drink restrictions, like alcohol?

Regulatory safety information advises that patients avoid consuming alcohol while taking this medication. Alcohol consumption may increase the severity of certain side effects, such as dizziness.

Q: Has Nicergoline Amel been studied in younger populations?

No. Official regulatory documents clearly state that the medicine is not recommended for use in pediatric patients (those under 18 years). This is due to a lack of established safety and efficacy data specifically for this age group.

Q: What is the longest time frame that Nicergoline Amel is typically prescribed for?

The official use protocol includes a standard 12-week review point to assess whether a clinical response has occurred. However, some clinical studies supporting the drug's use have involved observation periods extending up to 6 to 12 months to assess longer-term outcomes and safety profiles.

Q: Are there any specific lifestyle changes that complement the use of Nicergoline Amel?

While not drug-specific instructions, health authorities often provide general advice for conditions related to vascular and cerebral health. These recommendations typically include maintaining a healthy diet and engaging in regular physical exercise as measures that may complement overall vascular support.

Q: Is Nicergoline Amel considered a controlled substance?

No. Nicergoline is generally not listed as a controlled substance by major government drug control agencies. It is typically classified as a prescription-only (Rx) medicine, meaning its use requires professional supervision.

Q: How does Nicergoline Amel compare to ginkgo biloba in research studies?

Research has been conducted that includes comparisons between Nicergoline and other compounds used for similar conditions. Some clinical trials have specifically compared Nicergoline with Ginkgo biloba extract when studying outcomes related to blood flow and cognitive function.

Q: Is Nicergoline Amel used in other countries for different approved purposes?

Yes. While the main uses are centered around supporting vascular and cerebral health, the specific approved indications can vary depending on the country's national regulatory authority. The medicine is approved and used across many international jurisdictions.

Q: Is there a generic version of Nicergoline Amel available?

Yes. Since the patent for the active ingredient, Nicergoline, has expired in many regions, generic formulations are commonly available. These generics contain the same active ingredient as the brand-name product.

Q: What are the most frequent side effects reported in clinical trials?

Regulatory summaries of clinical data classify effects like dizziness, headache, nausea, and hypotension (low blood pressure) as the most frequent side effects documented during the drug’s clinical assessment. These are generally classified as common adverse reactions.

Q: Can Nicergoline Amel interact with common antidepressant medications?

Official documents warn of interactions with strong CYP2D6 inhibitors because Nicergoline is metabolized by this enzyme system. This class of inhibitors includes certain common antidepressant medications (e.g., Fluoxetine). The interaction may lead to increased Nicergoline exposure.

Q: Can Nicergoline Amel affect eye health or vision?

The drug's primary action includes supporting blood flow, and research has examined the use of Nicergoline for conditions related to insufficient blood flow affecting the eye. The medication has been studied in conditions like those affecting corneal health.

Q: What is the reason Nicergoline Amel is generally available only by prescription?

Nicergoline is classified as a prescription-only medicine (Rx) by regulatory authorities. This classification is typically due to its potent pharmacological properties, particularly its effects on the vascular system and its classification as an ergot derivative, which requires supervision by a healthcare professional.

Q: Is Nicergoline Amel ever used for tinnitus (ringing in the ears)?

Some medical information sources indicate that Nicergoline might be considered for symptoms like tinnitus. This is often based on the theory that tinnitus can be related to impaired blood flow in the inner ear, an area that is a focus of the drug's vascular action.

Q: Can Nicergoline Amel cause changes in mood or anxiety?

Research studies have evaluated the drug's effect on both behavioral symptoms and anxiety in the populations studied. Some studies have noted non-significant trends related to reducing behavioral symptoms, which can include those associated with mood.

How should Nicergoline Amel be stored and disposed of?

How to Store and Dispose of Nicergoline Amel?

Nicergoline tablets must be stored strictly according to the conditions documented in the medicine's official labeling to ensure product stability and safety. The primary storage rules are defined by temperature, light protection, and child safety requirements.

Storage and Handling

Requirement	Condition
Temperature	Store at room temperature.
Light Protection	The product must be protected from light to prevent discoloration and compound degradation.
Child Safety	Keep out of the sight and reach of children.
Container Rule	Store in the approved packaging.

Disposal Instructions

Unused or expired Nicergoline must be disposed of according to local regulations, typically by taking it to a designated treatment or disposal facility. The product must not be released into the environment, which includes disposal via household wastewater or general trash.

Nicergoline Amel